Human Longevity Stock
HealthTechLooking to sell Human Longevity stock or options?
Human Longevity has developed a biotechnology platform that merges genomic and phenotypic information to expedite the comprehension of human health. The platform focuses on addressing the age-related decline in inherent stem cell function and diseases like cancer, diabetes and obesity, heart and liver conditions, and dementia. By integrating DNA sequencing and expert analysis with machine learning, Human Longevity's platform empowers individuals to influence their health and facilitates the shift from reactive to proactive medical practices.
Robert Duggan, Surender Punia, Thierry Marbach, Bryan Johnson, BB Retail Capital, Reid Robison, Adam Hudson, Steven Kaplan, CONNECT (Accelerator), Roger Kaser, Katherine Santon, Singularity (Consulting Services (B2B)), StartUp Health, Daniel Curran, Peter Diamandis, San Diego Regional Economic Development Corporation, Ryan Chorazy, Shin Ryoku Trust, Synergy Growth, Rolf Mathies, Ping Wu, Oceanpine Healthcare Fund, Panacea Venture, Illumina, NKM Capital.